BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 30341790)

  • 1. The long and winding road towards epitope matching in clinical transplantation.
    Kramer CSM; Israeli M; Mulder A; Doxiadis IIN; Haasnoot GW; Heidt S; Claas FHJ
    Transpl Int; 2019 Jan; 32(1):16-24. PubMed ID: 30341790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-HLA Antibody: The Role of Epitopes in Organ Transplantation.
    Argani H
    Exp Clin Transplant; 2019 Jan; 17(Suppl 1):38-42. PubMed ID: 30777521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Defining the immunogenicity and antigenicity of HLA epitopes is crucial for optimal epitope matching in clinical renal transplantation.
    Kramer CSM; Roelen DL; Heidt S; Claas FHJ
    HLA; 2017 Jul; 90(1):5-16. PubMed ID: 28378521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Critical evaluation of a possible role of HLA epitope matching in kidney transplantation.
    Kumru Sahin G; Unterrainer C; Süsal C
    Transplant Rev (Orlando); 2020 Apr; 34(2):100533. PubMed ID: 32007300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel aspects of epitope matching and practical application in kidney transplantation.
    Lim WH; Wong G; Heidt S; Claas FHJ
    Kidney Int; 2018 Feb; 93(2):314-324. PubMed ID: 29061333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Towards the identification of the relative immunogenicity of individual HLA antibody epitopes.
    Kramer C; Heidt S; Claas FHJ
    Hum Immunol; 2019 Apr; 80(4):218-220. PubMed ID: 30735757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Which is the best predictor of de novo donor-specific antibodies in a cohort of non-sensitized first kidney transplantation: Antigenic, allelic, epitope, or physiochemical HLA mismatches?
    Delion A; Girerd S; Duarte K; Girerd N; Schikowski J; Kessler M; Frimat L; Aarnink A
    Clin Transplant; 2019 Apr; 33(4):e13508. PubMed ID: 30821002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Class II HLA epitope matching-A strategy to minimize de novo donor-specific antibody development and improve outcomes.
    Wiebe C; Pochinco D; Blydt-Hansen TD; Ho J; Birk PE; Karpinski M; Goldberg A; Storsley LJ; Gibson IW; Rush DN; Nickerson PW
    Am J Transplant; 2013 Dec; 13(12):3114-22. PubMed ID: 24164958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epitope analysis of HLA-DQ antigens: what does the antibody see?
    Tambur AR; Rosati J; Roitberg S; Glotz D; Friedewald JJ; Leventhal JR
    Transplantation; 2014 Jul; 98(2):157-66. PubMed ID: 25003284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Are We Ready for Epitope-Based HLA Matching in Clinical Organ Transplantation?
    Duquesnoy RJ
    Transplantation; 2017 Aug; 101(8):1755-1765. PubMed ID: 28207632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Terasaki Epitope Mismatch Burden Predicts the Development of De Novo DQ Donor-Specific Antibodies and are Associated With Adverse Allograft Outcomes.
    Willicombe M; Blow M; Santos-Nunez E; Freeman C; Brookes P; Taube D
    Transplantation; 2018 Jan; 102(1):127-134. PubMed ID: 28731902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Definition of permissible and immunogenic HLA antigens based on epitope analysis of the HLA specific antibodies produced in sensitized patients.
    Papassavas AC; Stavropoulos-Giokas C; Boletis J; Ioannou S; Iniotaki-Theodoraki A; Kostakis A
    Eur J Immunogenet; 2002 Oct; 29(5):401-7. PubMed ID: 12358849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of amino acid mismatch in the UNOS dataset.
    Sasaki N; El-Awar N; Idica A
    Clin Transpl; 2011; ():299-309. PubMed ID: 22755423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HLAMatchmaker-based definition of structural human leukocyte antigen epitopes detected by alloantibodies.
    Duquesnoy RJ; Marrari M
    Curr Opin Organ Transplant; 2009 Aug; 14(4):403-9. PubMed ID: 19417654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epitope Analysis Aids in Transplant Decision Making by Determining the Clinical Relevance of Apparent Pre-Transplant Donor Specific Antibodies (DSA).
    Pandey S; Harville TO
    Ann Clin Lab Sci; 2019 Jan; 49(1):50-56. PubMed ID: 30814077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kidney allocation based on proven acceptable antigens results in superior graft survival in highly sensitized patients.
    Heidt S; Haasnoot GW; van Rood JJ; Witvliet MD; Claas FHJ
    Kidney Int; 2018 Feb; 93(2):491-500. PubMed ID: 28947279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Comprehensive Evaluation of the Antibody-Verified Status of Eplets Listed in the HLA Epitope Registry.
    Bezstarosti S; Bakker KH; Kramer CSM; de Fijter JW; Reinders MEJ; Mulder A; Claas FHJ; Heidt S
    Front Immunol; 2021; 12():800946. PubMed ID: 35154076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HLA epitopes as viewed by antibodies: what is it all about?
    Tambur AR; Claas FH
    Am J Transplant; 2015 May; 15(5):1148-54. PubMed ID: 25708017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HLA epitope matching in pediatric renal transplantation.
    Sypek MP; Hughes P; Kausman JY
    Pediatr Nephrol; 2017 Oct; 32(10):1861-1869. PubMed ID: 27995324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reappraisal of HLA antibody analysis and crossmatching in kidney transplantation.
    Lee PC; Ozawa M
    Clin Transpl; 2007; ():219-26. PubMed ID: 18642453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.